Molecular profiling of small cell lung cancer in a Japanese cohort

Lung Cancer

Volumn 84, Issue 2, 2014, Pages 139-144

  Wakuda, Kazushige ^a   Kenmotsu, Hirotsugu ^a   Serizawa, Masakuni ^a   Koh, Yasuhiro ^a   Isaka, Mitsuhiro ^a   Takahashi, Shoji ^a   Ono, Akira ^a   Taira, Tetsuhiko ^a   Naito, Tateaki ^a   Murakami, Haruyasu ^a   Mori, Keita ^a   Endo, Masahiro ^a   Nakajima, Takashi ^a   Ohde, Yasuhisa ^a   Takahashi, Toshiaki ^a   Yamamoto, Nobuyuki ^a,b  

^a SHIZUOKA CANCER CENTER   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Driver mutation; EGFR; Genomic aberration; Molecular profiling; PIK3CA; Small cell lung cancer

Indexed keywords

NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; TUMOR PROTEIN;

ADULT; AGED; AKT1 GENE; ALK GENE; ARTICLE; BRAF GENE; CANCER SURGERY; EGFR GENE; FEMALE; FGFR1 GENE; FGFR2 GENE; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENETIC TRANSCRIPTION; GENOTYPE; HER2 GENE; HUMAN; HUMAN TISSUE; JAPANESE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEK1 GENE; MIDDLE AGED; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RET; PIK3CA GENE; PLEURA EFFUSION; PRIORITY JOURNAL; PTEN GENE; ROS1 GENE; VERY ELDERLY; COHORT ANALYSIS; GENETIC ASSOCIATION; GENETICS; JAPAN; LUNG TUMOR; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; SMALL CELL LUNG CANCER;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM PROTEINS; SMALL CELL LUNG CARCINOMA;

EID: 84899491337     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.02.013     Document Type: Article

References (31)

1. van Meerbeeck J.P., Fennell D.A., De Ruysscher D.K. Small-cell lung cancer. Lancet 2011, 378(9804):1741-1755.
2. Puglisi M., Dolly S., Faria A., Myerson J.S., Popat S., O'Brien M.E. Treatment options for small cell lung cancer - do we have more choice?. Br J Cancer 2010, 102(4):629-638.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
4. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
5. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
6. Maemondo M., Inoue A., Kobayashi K., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
7. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742.
8. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246.
9. Ettinger D.S., Akerley W., Borghaei H., Chang A.C., Cheney R.T., Chirieac L.R., et al. Non-small cell lung cancer. J Natl Compr Cancer Netw 2012, 10(10):1236-1271.
10. Peters S., Adjei A.A., Gridelli C., Reck M., Kerr K., Felip E. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7):vii56-vii64.
11. Planchard D., Le Pechoux C. Small cell lung cancer: new clinical recommendations and current status of biomarker assessment. Eur J Cancer 2011, 47(Suppl. 3):S272-S283.
12. Serizawa M., Koh Y., Kenmotsu H., Isaka M., Murakami H., Akamatsu H., et al. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective single-institute study cancer 2014, (in press).
13. Sun Y., Ren Y., Fang Z., Li C., Fang R., Gao B., et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010, 28(30):4616-4620.
14. Li C., Fang R., Sun Y., Han X., Li F., Gao B., et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE 2011, 6(11):e28204.
15. Peifer M., Fernandez-Cuesta L., Sos M.L., George J., Seidel D., Kasper L.H., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012, 44(10):1104-1110.
16. Rudin C.M., Durinck S., Stawiski E.W., Poirier J.T., Modrusan Z., Shames D.S., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012, 44(10):1111-1116.
17. Umemura S., Goto K., Mimaki S., Ishii G., Ohmatsu H., Niho S., et al. Comprehensive genomic analysis of small cell lung cancer in Asian patients. ASCO Meet Abstr 2013, 31(Suppl. 15):7512.
18. Okudela K., Suzuki M., Kageyama S., Bunai T., Nagura K., Igarashi H., et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007, 57(10):664-671.
19. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4(4):257-262.
20. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304(5670):554.
21. Wojtalla A., Fischer B., Kotelevets N., Mauri F.A., Sobek J., Rehrauer H., et al. Targeting the phosphoinositide 3-kinase p110-alpha isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer. Clin Cancer Res 2013, 19(1):96-105.
22. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8(8):627-644.
23. Gonzalez-Angulo A.M., Juric D., Argiles G., Schellens J.H., Burris H.A., Berlin J., et al. Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: results from the first-in-human study. ASCO Meet Abstr 2013, 31(Suppl. 15):2531.
24. Omlin A.G., Spicer J.F., Sarker D., Pinato D.J., Agarwal R., Cassier P.A., et al. A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors. ASCO Meet Abstr 2012, 30(Suppl. 15):3022.
25. Tatematsu A., Shimizu J., Murakami Y., Horio Y., Nakamura S., Hida T., et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008, 14(19):6092-6096.
26. Fukui T., Tsuta K., Furuta K., Watanabe S., Asamura H., Ohe Y., et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci 2007, 98(11):1714-1719.
27. Pujol J.L., Quantin X., Jacot W., Boher J.M., Grenier J., Lamy P.J. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003, 39(2):131-138.
28. Jorgensen L.G., Osterlind K., Genolla J., Gomm S.A., Hernandez J.R., Johnson P.W., et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 1996, 74(3):463-467.
29. Ignatius Ou S.H., Zell J.A. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. J Thorac Oncol 2009, 4(3):300-310.
30. Kenmotsu H., Serizawa M., Koh Y., Isaka M., Takahashi T., Murakami H., et al. Concordance between formalin-fixed paraffin-embedded biopsy samples and surgically resected snap-frozen samples in multiplexed molecular profiling of lung cancers. ASCO Meet Abstr 2013, 31(Suppl. 15):e18556.
31. Koh Y., Kenmotsu H., Serizawa M., Isaka M., Mori K., Imai H., et al. Identification of actionable mutations in surgically resected tumor specimens from Japanese patients with non-small cell lung cancer by ultra-deep targeted sequencing. ASCO Meet Abstr 2013, 31(Suppl. 15):7572.